Published in Cancer Vaccine Week, September 5th, 2005
"The purpose of this study was to investigate the synergistic anti-tumor effect of PA and DOX on K562, A549 and CNE cells in vitro and experimental transplantation Sarcoma 180 (S180) and Hepatoma 22 (H22) in vivo and to explore the mechanism of its action. PA 12.5 approximately 100 mg/L inhibited proliferation of K562, A549, and CNE cells in vitro in a time- and concentration-dependent manner as determined by the microculture tetrazolium (MTT) assay," investigators in the People's Republic of China reported.
"A combination of PA 12.5, 25 mg/L with DOX .01...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.